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Abstract
Introduction: Delays in adequate antimicrobial treatment contribute to high cost and mortality in sepsis.
Polymerase chain reaction (PCR) assays are used alongside conventional cultures to accelerate the identification of
microorganisms. We analyze the impact on medical outcomes and healthcare costs if improved adequacy of
antimicrobial therapy is achieved by providing immediate coverage after positive PCR reports.
Methods: A mathematical prediction model describes the impact of PCR-based rapid adjustment of antimicrobial
treatment. The model is applied to predict cost and medical outcomes for 221 sepsis episodes of 189 post-surgical
and intensive care unit (ICU) sepsis patients with available PCR data from a prospective, observational trial of a
multiplex PCR assay in five hospitals. While this trial demonstrated reduction of inadequate treatment days, data on
outcomes associated with reduced inadequate initial antimicrobial treatment had to be obtained from two other,
bigger, studies which involved 1,147 (thereof 316 inadequately treated) medical or surgical ICU patients. Our results
are reported with the (5% to 95%) percentile ranges from Monte Carlo simulation in which the input parameters
were randomly and independently varied according to their statistical characterization in the three underlying
studies. The model allows predictions also for different patient groups or PCR assays.
Results: A total of 13.1% of PCR tests enabled earlier adequate treatment. We predict that cost for PCR testing
(300 €/test) can be fully recovered for patients above 717 € (605 € to 1,710 €) daily treatment cost. A 2.6% (2.0 to
3.2%) absolute reduction of mortality is expected. Cost per incremental survivor calculates to 11,477 € (9,321 € to
14,977 €) and incremental cost-effectiveness ratio to 3,107 € (2,523 € to 4,055 €) per quality-adjusted life-year.
Generally, for ICU patients with >25% incidence of inadequate empiric antimicrobial treatment, and at least 15%
with a positive blood culture, PCR represents a cost-neutral adjunct method.
Conclusions: Rapid PCR identification of microorganisms has the potential to become a cost-effective component
for managing sepsis. The prediction model tested with data from three observational trials should be utilized as a
framework to deepen insights when integrating more complementary data associated with utilization of molecular
assays in the management of sepsis.
Introduction
Inadequate antimicrobial treatment has been identified
as an important factor contributing to mortality in sep-
sis [1]. The rates of initial inadequate empiric antimicro-
bial treatment in hospitals vary and are often reported
to be in the range of 15 to 30% [2-6]. Early adequate
antimicrobial treatment in septic shock patients is
crucial, as mortality increases by 7.6% each hour of
delay after onset of hypotension [5]. However, current
laboratory methods of microbiologic testing are very
time consuming [7,8] and lack sensitivity [7,9,10]. Physi-
cians therefore start, and frequently also modify [11],
empiric antibiotic therapy without an identification of
the relevant microorganism.
There is a growing body of literature comparing BC
and PCR methods and sketching potential clinical appli-
cations [12-16]. However, none of these papers was able
to quantify the expected effects. The first demonstration
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of how a multiplex PCR assay is able to differentially
identify sepsis patients who could benefit from a prede-
fined intervention was [17], observing that 36.4 (22 to
51) days of early inadequate treatment could be elimi-
nated per 100 PCR tests performed in the ICU if the
rapidly available PCR results were used to adjust
treatments.
Published interventional data using the new treatment
modality are still lacking. For the time being, we, there-
fore, must bridge an important gap by assuming that
the association between early inadequate treatment and
elevated mortality and morbidity as observed in other
trials [3,4,18-22] is applicable to the patient cohort
which can be moved from inadequate to adequate treat-
ment via utilization of PCR results.
The goal of this paper is to synthesize available knowl-
edge into predictions of cost and of mortality impact of
PCR testing in the management of sepsis, and to provide
a framework for future inclusion of more forthcoming
data in this novel and clinically interesting field.
Materials and methods
Study design and patients
This study builds on data of a previous study [17],
including all post-surgical and ICU patients from two
German, one Italian, one Spanish and one US hospital
of this previous study in which a multiplex PCR test
(LightCycler SeptiFast test, Roche Diagnostics, Penzberg,
Germany) was performed in parallel to the first blood
culture in a sepsis episode. Approval to use these data
for re-analysis in the present study was obtained. The
potential impact of utilizing all PCR reported findings to
provide rapid coverage for these microorganisms and
their potential resistances (according to the local or
regional resistance data for the PCR reported microor-
ganism) was evaluated. Furthermore, this study makes
use of pooled data on outcomes associated with inade-
quate treatment from two earlier trials with combined
1,147 medical or surgical ICU patients (of which 316
were inadequately treated) [3,4]. Approval to use these
data for re-analysis in the present study was obtained.
Below, we describe the models built for predicting
cost-effectiveness from a perspective of total healthcare
cost. Note that our cost impact and mortality predic-
tions are independent, that is, our analysis attempts to
justify cost with either one of these effects.
For mortality analysis the event of non-survival is
assigned to the last episode with inadequate treatment
within 30 days of death, or to the last episode if all were
adequately treated, so double-counting of non-survivals
is avoided.
The PCR assay [23] is available as CE marked diagnos-
tic reagent in Europe and some other countries, but at
this time is not available for diagnostic use in the USA.
Cost impact prediction
We develop a quantitative description of how PCR may
trigger lower morbidity and hence lower treatment cost,
which may balance the incremental laboratory cost.
Parameters we use are listed in Table 1. Full cost per
PCR test, Costt, is calculated according to Additional
data file 1. According to the investigated treatment algo-
rithm, only one PCR test is used per treatment episode
to optimize antimicrobial therapy. The overall cost
impact can be described with Equation 1.
Impact N Cost Savepis t trig= −* ( ) (1)
Nepis is the total number of episodes (and tests) in
which blood cultures are complemented by PCR testing
for managing early antimicrobial treatment in sepsis.
For calculating the mean savings a PCR test triggers,
Savtrig, we developed Equation 3: Savings can only occur
in those patients who are PCR positive (PCR+) and on
inadequate ("IA”) empiric treatment (the first two fac-
tors in Equation 3). The parameter DG describes the
mean days gainable on early adequate treatment (Table
1, Equation 2).
DG Du
TAT
PCR
IA PCR
= −+( )24
(2)
The factor FLOS
IA translates days on earlier adequate
treatment into outcome in terms of days of reduced
length of stay (LOS). It is calculated by dividing the mean
ICU-LOS reduction by the mean duration of inadequate
empiric treatment, DuPCR
IA
+ ([3,4,17]; Table 1).
If the savings which can be realized per day of
reduced stay, Savd, are known, the resulting savings trig-
gered per PCR test done, Savtrig, can be calculated
according to:
Sav Sh In DG F Savtrig PCR PCR
IA
LOS
IA
d= + +* * * * (3)
However, the savings which can be realized per day of
reduced stay, Savd, are highly variable. Therefore, rather
than attempting to determine the overall cost impact we
conducted a break-even analysis. Zero overall cost
results according to Equation 1 when the savings trig-
gered per PCR test equals the cost per PCR test, that is,
when Savtrig= Costt. The value for Savd which results
with that substitution in Equation 3 is defined as the
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break-even cost-savings per day of LOS reduction, Savbe
(Equation 4). Essentially, patients with that mean daily
cost or higher can receive PCR testing without incurring
net cost.
Savbe
ost
Sh In DG F
t
PCR PCR
IA
LOS
IA=
+ +
C
* * *
(4)
Mortality prediction
In the following we describe how PCR may trigger lower
mortality, and quantify the related cost-effectiveness.
Parameters we use are listed in Table 1. Cost per incre-
mental survivor can be determined according to Equa-
tion 5 when dividing the incurred cost by the number of
incremental survivors. For calculating the number of
incremental survivors, we developed the denominator of
Equation 5. With the investigated PCR based treatment
algorithm, a mortality effect can only occur in the
cohort of inadequately treated PCR+ patients (first three
factors in the denominator of Equation 5. The mortality
observed in this cohort within 30 days of discontinuing
antimicrobial treatment should be reduced according to
the relative risk of non-survival, RR†, when comparing
inadequately to adequately empirically treated cohorts
[3,4]. Using this assumption, the fraction of incremental
survivors is calculated by the factor ( M MRRPCR
IA PCR
IA
+
+
− †
) in
Equation 5.
Costsurv
N ost
N Sh In M
M
epis t
epis PCR PCR
IA
PCR
IA PCR
IA=
+ + +
+
−
* C
* * *(
RR
DG
DuPCR
IA†
)*
+
(5)
The last factor in the denominator, DGDuPCRIA + , is always
smaller than one and thus reduces the theoretical mor-
tality effect which would result in immediate adequate
treatment but cannot be fully achieved due to the time
(hours) needed to obtain PCR results, TATPCR. (see
Equation 2). The linear correlation between delay of
adequate treatment and outcome that we imply is sup-
ported by data from an animal model of sepsis [24] and
also evidenced with human data [25]. N epis was left in
Equation 5 for easier understanding, but can be can-
celed out.
The incremental cost effectiveness ratio (ICER) is
commonly defined by Equation 6 and follows when
dividing cost per incremental survivor (as determined
with Equation 5) by gainable quality-adjusted life-years
(QALY) per incremental survivor. QALY were not obser-
vable in our non-interventional data. See Table 1 for our
data source for mean number of life-years for sepsis sur-
vivors of the applicable age group, and for the discount
factor for reduced quality of life after an ICU stay for
sepsis, Utilityhealth-state.
ICER ostQALY
ost
Lifeyears Utility
surv
gained survivor heal
= =
C C
*/ th state−
(6)
Table 1 Parameters used to calculate cost impact and cost-effectiveness
Parameter Description Unit Value Source Used in
equation
Cost t Full cost per PCR test € 300 Additional file
1
1, 4, 5,
DG Days gainable on adequate treatment when utilizing PCR+ information day 2.78 = 80.5/29 [17]a 2,3,4
DuPCR
IA
+
Mean total duration of inadequate treatment (as observed in PCR+ episodes
with 0.5 ≤Du IA ≤ 7.5)
day 3.28 = 0.5 + DG [17]a 2, 5,
FLOS
IA Factor which translates days on earlier adequate treatment into outcome in
terms of mean days reduced length of stay (deltaLOS = LOSInad - LOSAd)
- 1.15 = 3.763 day/
3.276 day
=
+
deltaLOS
DuPCR
IA
calculated
from [3,4,17]
3, 4
InPCR
IA
+
Incidence of inadequate treatment in the PCR+ group - 0.397 = 29/73 Figure 1 4, 5
LY gained Mean # years survival of survivors of ICU sepsis, age cohort >60
c yr 5.43 b = 12.3 *
488/1105
[26] 6
MPCR
IA
+
Mortality rate of inadequately treated PCR+ patients - 0.414 = 12/29 Figure 1 5
RR† Relative risk of non-survival (@ inadequate/adequate treatment) - 2.315 [3,4,17] pooled 5
Sh PCR+ Share of episodes with at least 1 PCR+ microorganism - 0.330 = 73/221 Table 2 4, 5
TATPCR Time between PCR sampling and result reported (hours) hr 12 [17] 2
Utility health.
state
Health state utility after ICU sepsis QALY/
yr
0.68 [26] 6
a Not identical with time to positive blood culture, but linked to it in about 50% of contributing data
b LYgained (of survivors age >60, according to data from [26]); = LYgained (all included sepsis survivors)* ICER(all)/ICER(age >60) = 12.3 yr * 48,800 $/110,500 $ =
5.43 yr.
c We use the data for those aged >60 because the mean age in our subgroup with potential survival benefit (Table 3) is 69.1 yr.
€, Euro (European currency unit); QALY, quality-adjusted life year.
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Statistical analysis
To characterize the uncertainty of predicted results, we
re-iterated all calculations while the input parameters
were randomly and independently varied using their
binomial, multinomial and log-normal distributions, as
deducted from the respective statistical characteriza-
tions in [3,4,17]. Results from [4] and [3] have been
pooled. In each such Monte Carlo simulation 1,000
samples have been generated, each with 1,000 patients.
The (5% to 95%) percentile ranges for the predicted
results are reported in the manuscript. All calculations
were done with SAS version 9.1.3 (SAS Institute, Cary,
NC, USA). Sensitivity of results to patient cohort char-
acteristics is explored by making use of Equations 4, 5
and 6.
Results
Prediction of impact on morbidity, length of ICU stay and
cost
In 74 of 221 episodes, antimicrobial treatment was mod-
ified after more than 12 hours of empiric initial treat-
ment in order to cover different suspected or culture-
determined microorganisms or resistances. PCR results
(Table 2) suggested in 29 of these 74 episodes (Figure 1)
equivalent antimicrobial adjustments earlier. As a conse-
quence, 80.5 days (CI 48 to 113 days) potential earlier
adequate treatment were enabled by 221 PCR tests [17],
with associated costs of 66,300 €.
To translate earlier adequate treatment into a clinical
outcome measure, we use the factor FLOS
IA (Table 1)
that predicts 1.15 days (1.02 to 1.64 days) shorter dura-
tion of ventilation and ICU stay for each day of earlier
adequate treatment, or 92.5 days in total. Hence, the
costs associated with PCR testing could be fully recov-
ered in departments with mean daily treatment costs
above 717 € (605 € to 1,710 €) (Equation 4 with inputs
of Table 1).
Correcting inadequate coverage of a Gram-positive
pathogen by multiplex PCR contributed 38.2% to the
reported cost-effectiveness; the contributions of acceler-
ated Gram-negative or antifungal coverage were 46.3%
and 15.5%, respectively.
Generally, for any sepsis patient cohort characterized
by incidence of antimicrobial modifications (x-axis) and
observed BC+ share (curves), Figure 2A allows to esti-
mate which mean daily treatment cost savings would be
required in order to recover the PCR related costs.
Figure 1 Modification of empiric antimicrobial treatment and microbiological characterization: Among 221 investigated sepsis episodes,
74 (33.5%) required modification of empiric antimicrobial treatment (upper circle). Positive blood cultures (lower right circle) triggered 27 (= 8 +
19) of these changes. Among 73 PCR+ episodes (lower left circle), 29 (= 10 + 19) allowed earlier adequate treatment (data from [17]). In brackets:
Non-survivors within the respective groups.
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Prediction of impact on mortality
Thirty-day non-survival was observed in or after 26.7%
(59/221) of all episodes, and 32.9% (24/73) of PCR+ epi-
sodes (Figure 1). Of 73 PCR+ episodes, 44 (thereof 12
non-survivals; Figure 3A) were adequately treated and
hence without potential impact from PCR. However, in
29 inadequately treated PCR+ episodes (Figure 3, IA),
another 12 non-survivors were observed without PCR
based intervention (Table 3). The earlier adequate treat-
ment facilitated by the PCR+ results translates into five
lives potentially saved (Figure 3A*) if we use the relative
risk of non-survival associated with initial inadequate
treatment of 2.32 (CI 1.96 to 2.74; P < 0.001), as estab-
lished previously [3,4]; furthermore, we factored in a
correction because PCR+ driven adjustments are not
immediate (Equation 5). Our prediction translates into
an absolute reduction of mortality by 2.6% points (2.0 to
3.2%).
With full cost associated with PCR testing of 300
€/test, the cost per incremental survivor calculates to
11,477 € (9,321 to 14,977 €) (Equation 5 with inputs of
Table 1). To determine the incremental cost-effective-
ness ratio (ICER) of 3,107 € per QALY (2,523 to 4,055
€/QALY) we used Equation 6 with data on life-years for
a cohort of survivors of severe sepsis aged >60 from
reference [26] (Table 1).
Figure 2B allows us to estimate the cost per incremen-
tal survivor when the PCR method is used in any severe
sepsis patient cohort (with about 30% mortality) that
can be characterized by incidence of antimicrobial mod-
ifications (x-axis) and observed BC+ share (curves).
Potential risk of false-positive PCR results
In the post-surgical and ICU group of patients we saw a
concurrent risk of unnecessary rule-in of extended anti-
microbials in 6 of 221 episodes.
Discussion
We believe that our paper (a) represents the first quanti-
tative evaluation of expected cost and outcomes from
PCR-based interventions in sepsis; (b) offers a frame-
work to assess which patient groups might benefit most;
(c) can provide valuable guidance, notably when design-
ing and evaluating interventional trials that incorporate
PCR into managing antimicrobial treatment in sepsis;
and (d) will lend itself to assess relative utility and cost-
effectiveness of alternative molecular diagnostics assays.
The investigated PCR assay identified patients who
could benefit from a predefined intervention. Among 73
episodes with 87 positive PCR findings, in 29 the infor-
mation gain was useful as there was a need to alter the
antimicrobial treatment. Other authors have observed
rates of inadequate coverage of similar magnitude in
blood culture positive patients in ICUs [2-6,27]. How-
ever, a concurrent risk of over-treatment was observed
[17]. The unnecessary rule-in of extended antimicrobials
(vancomycin, oxazolidinone, piperacillin/tazobactam, a
carbapenem, or an antifungal; [17]) in 6 of 221 episodes
are +2.3% on top of the 260 empiric courses of extended
treatment in our trial, that is, a comparatively small
incremental burden of cost for antimicrobials or of deal-
ing with incremental side-effects. While cost for antimi-
crobial drugs are expected to rise in the early treatment
Table 2 Underlying diagnoses and identification of clinically significant microorganisms in 221 ICU or surgical ward
episodes (subset of data reported earlier [17])
Totals PCR +
episodes
Share of PCR+ epsiodesb ShPCR
+
BC+
episodes
Share of BC+
epsiodesb
ShBC+
Total a 221 73 0.33 44 0.20
Underlying diagnoses a
- Intra-abdominal sepsis 87 31 0.36 22 0.25
- Nosocomial pneumonia 80 28 0.35 21 0.26
- Community acquired pneumonia 6 1 0.17 0 0
- Multi-organ dysfunction syndrome 7 4 0.57 4 0.57
- Catheter related sepsis; post cardiac
surgery
45 18 0.40 9 0.20
- Neutropenic fever 15 5 0.33 2 0.13
- Bone/joint infection 9 4 0.44 0 0
Other 46 11 0.24 3 0.07
a underlying diagnoses do not add up to totals due to dual conditions
b at least one clinically significant microorganism retrieved in one PCR, respectively in any of several (as in standard of care) BC tests.
BC, blood culture (BC+: blood culture with clinically relevant microorganism identified, not counting contaminations that are immediately at reporting evident to
the treating clinician); PCR, polymerase chain reaction (PCR+: PCR with clinically relevant microorganism identified. Note that in our study, all PCR+ reported
microorganisms are considered clinically relevant.
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days, we hypothesize that overall the burden of unneces-
sary extended treatment will be reduced by utilization of
PCR+ information for earlier adequate treatment. The
aspect of false positive PCR assays and differential costs
for antimicrobial drugs was not included the cost analy-
sis. These secondary effects are to look for in future
interventional trials.
We did not make any use of negative PCR findings.
Single or consecutive negative PCR findings in certain
patient types and clinical situations may be useful for
early de-escalation strategies of antimicrobial treatment.
However, our data show 11 cases of positive blood cul-
ture with negative PCR assay (Figure 1). Therefore, we
conclude withdrawal of antimicrobial treatment upon a
PCR negative result is not recommended. Furthermore,
regarding the overall effect, it would be entirely possible
that inadequate discontinuation after PCR negative
results would cancel out the improved treatment from
PCR positive findings.
Given the expected minor impact on drug cost, but
high efforts required for the multiplex PCR method in
the laboratory [23], significant concerns about cost-
effectiveness prevail [28]. We demonstrate that
improved morbidity through earlier adequate treatment
Figure 2 Impact from PCR testing. Diagrams for estimating impact from PCR testing in sepsis, based on incidence of modification of initial
antimicrobial treatment (x-axis) and share of episodes with positive blood culture (curves): A: Cost-neutral application of PCR is predicted if the
mean daily treatment cost of those included in PCR testing exceeds the break-even value on the y-axis (A). Data point from our study: 717 €, at
20% BC+ (Table 2) and 33.5% modification of empiric treatment (= 74/221, Figure 1). B: Cost per incremental survivor is predicted as indicated
on the y-axis (B). Data point from our study: 11,477 €, at 20% BC+ and 33.5% modification of empiric treatment. Figure 2 was calculated using
equation 4 (A) and equation 5 (B) with substitution terms as given in Additional data file 2.
Figure 3 Predicted mortality reduction. Predicted mortality
reduction if earlier adequate treatment is achieved in 29 of the 73
PCR+ episodes: A: Under adequate treatment, a 27.3% mortality is
observed (= 12/(12 + 32)); IA: In the inadequately treated (IA) group,
a mortality of 41.4% is observed (= 12/(12 + 17)); A*: A PCR+ based
intervention should reduce the mortality in the former IA group
according to equation 5 and the reduced relative risk of dying, RR†
(from [3,4]). We predict that 5 of the 12 (Table 3) non-survivors
might have survived if the PCR+ results were interventionally used.
The resulting mortality of 26.0% (= (12 + 7)/73) is comparable to
the mortality observed under adequate treatment (A).
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leads to full recovery of PCR cost for the patients stu-
died by us if their mean daily cost was at least 717 €
(605 € to 1,710 €). In the ICU, where daily costs exceed
1,710 € [29], there is over 95% likelihood of lowered
overall cost. For different patients than those included
in our five study sites, Figure 2A can be used for defin-
ing whether PCR testing should be implemented. In
clinical reality, the actual value of a freed-up ICU bed
will vary, but it should not be underestimated: Accord-
ing to a recent study [30], discharge from the intensive
care unit at a time of no vacancy was a significant risk
factor for intensive care unit readmission or unexpected
death.
Mostly, we studied ICU patients with predominantly
hospital-acquired infections, not community-acquired. For
the latter, the rate of initial inadequate treatment typically
is lower [4]. Furthermore, the daily average treatment cost
of community-acquired infections might be less than hos-
pital-acquired. However, both inadequate rate and daily
treatment cost are key determinants of cost effectiveness
(see Equation 4). Equation 4 can be employed to predict
cost effectiveness for community acquired infections if the
input data, such as rate of inadequate treatment and aver-
age daily treatment cost are known.
Another hidden cost of inappropriate antimicrobial
therapy is the increasing prevalence of Clostridium diffi-
cile associated diarrheal illness. Savings could be gener-
ated from lower C. difficile incidence with lower rate of
inadequate antimicrobial treatment. This aspect is not
included in our model as only interventional studies
would allow quantitative observations.
Besides the cost impact, we analyzed the potential of
the new method to lower mortality from sepsis. The
predicted 2.6% (2.0 to 3.2%) absolute reduction of mor-
tality in the PCR-tested patients could be considered a
relevant contribution to the Surviving Sepsis Campaign
[21,31]. In big patient cohorts with severe sepsis, inade-
quate antimicrobial treatment has been identified as
independent predictor of mortality [21,32]. Specifically
in septic shock, Kumar et al. [5] observed an increase of
mortality by 7.6% each hour of delay after onset of
hypotension. While the PCR method with its minimum
turn-around time of 6.3 hrs [33] seems not well-suited
for becoming focused on septic shock patients, shock
survivors still might recover faster after the PCR+ trig-
gered earlier treatment adjustment. Therefore we con-
clude that the principal use of the method should be
broad and early in sepsis and severe sepsis, so the
Table 3 Characteristics of 12 non-survivors observed in 29 inadequately treated PCR+ patients
Age Co-morbidity Infectious focus PCR+ pathogen a # days
gainable b
Evidence for PCR+ relevance c
BC+ Other test
74 Pleural lesion Peritonitis Aspergillus, Candida 4 Candida Aspergillus antigen+
79 Decompensated heart
(right side)
Cholangitis Pseudomonas,
(Escherichia coli)
7 Pseudomonas Bile- duct cul+
66 Liver transplantation Peritonitis Stenotropho-monas 4 Stenotropho-monas, Tracheal swab cul+
77 Hemodialysis Catheter-related CoNS d 2 CoNS (2×) Pos. tracheal swab cul+
47 Trauma Pneumonia CoNS d 2 CoNS, Pseudomonas Catheter-tip CoNS+
55 Poly-trauma Abdominal (late
detected)
Enterobacter 7 Enterobacter Enterobacter in cul+
62 Cardiothoracic surgery Pneumonia;
unclear: 2nd focus
Staph.aureus: MRSA 2 MRSA+ (3×) Thorax, sternum cul+
58 Artherosklerosis Pneumonia Aspergillus 2.5 - Bronchial aspirate cul+
78 Rectal neo-plasm;
perforat-ed abscess
Intra-abdominal Enterococcus faecium 1.5 Enterococcus faecium
(post mortem)
Enterococcus faecalis in
drainage cul+
85 Cardiac surgery Pneumonia Klebsiella 3 Enterobacter (equivalent the-
rapy change )
71 Bypass surgery Pneumonia Enterococcus faecalis;
(Pseudomonas)
3 Enterococcus faecalis Pseudomonas in cul+
77 Cardiac surgery Pneumonia Klebsiella 5 Klebsiella Klebsiella in cul+
a Insufficiently empirically covered PCR+ microorganisms, and (concurrent other PCR+ microorganism).
b Days gainable on early adequate coverage if the PCR+ information is utilized.
c Main evidence is the clinical course associated with antimicrobial treatments. In the columns below we report other laboratory findings that suggested drug
changes equivalent to those PCR could have triggered earlier (see column #days gainable).
d in PCR+: above manufacturer cut-off for CoNS.
BC+, blood culture with clinically relevant microorganism identified, not counting contaminations that are immediately at reporting evident to the treating
clinician; CoNS, coagulase-negative Staphylococcus; cul+, microorganisms found in cultures of specimen other than positive cultures; MRSA, methicillin-resistant
Staphylococcus aureus; PCR, polymerase chain reaction (PCR+: PCR with clinically relevant microorganism identified. Note that in our study, all PCR+ reported
microorganisms are considered clinically relevant
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progression of disease towards septic shock might be
reduced.
For the 29 post-surgical or ICU patients with potential
PCR+ impact we observed a mortality of 41.4% (Figures
1 and 3). To predict the potential mortality reduction
from PCR+ triggered earlier adequate treatment, we
used a relative risk of non-survival between immediate
and delayed adequate antimicrobial treatment (RR†) of
2.32 (CI 1.96 to 2.74; P < 0.001). This is well within the
range of observations given in literature for this relative
risk, typically in the range of 1.3 to 3.8 [20-22], but even
up to 10 [19]. A statistically analyzed multi-center data-
set reported by Harbarth et al. [32], with attention paid
also to isolating confounding variables, yielded a RR† of
1.8; it might be a better estimate than the one we used;
however, the resulting cost per incremental survivor of
14,670 € is in the magnitude of our calculated result
(Figure 2B). To determine the incremental cost-effec-
tiveness ratio (ICER) we used data on life-years after
ICU for a cohort aged >60. If younger patients were
included [26], or if following other references [34], sig-
nificantly lower ICER results would be obtained (1,350
or 1,053 €/QALY instead of 3,107 €/QALY).
The cost per incremental survivor of 11,477 € (9,321 €
to 14,977 €) and incremental cost-effectiveness ratio
(ICER) of 3,107 € (2,523 € to 4,055 €) per quality-
adjusted life-year that we predict are well below what
has been reported for other sepsis-related strategies,
notably for drotrecogin alfa (activated) [26,35,36]. In
hospitals where this drug is used as rescue strategy in
late Sepsis stages, utilizing PCR as adjunct should ele-
vate the overall cost-effectiveness while probably
improving the overall mortality outcome further.
A key limitation of our study is that we have to resort
to published data from ICU cohorts, notably [3,4], to
obtain a hypothesis about how earlier adequate treat-
ment translates into reduced morbidity and mortality.
Whether the differences observed between the included
ICU cohorts were sufficiently balanced with respect to
potential confounders, and whether they apply when we
move about 40% of them (Figure 1, 40% = (10 + 19)/74)
towards earlier adequate treatment, introduces uncer-
tainty into our quantitative prediction.
We reported two independent predictions about the
balance of incremental costs and effects from PCR test-
ing. Taken in combination, cost-effective application will
result with patients that are characterized by lower daily
treatment cost, inadequate treatment rate and BC+ or
PCR+ rate.
Conclusions
Our analysis of observational data allows plausible pre-
dictions, characterizes patient groups of interest, and is
balanced with respect to the sensitivity of results to key
input. PCR detection promises to be cost-effective for
improving antimicrobial treatment and medical outcome
for septic post-surgical and ICU patients. However, pro-
spective interventional studies are now needed to com-
plement the insights regarding clinical benefit and cost-
effectiveness of multiplex PCR-based diagnosis to
improve adequacy of antimicrobial treatment.
Key messages
• Multiplex PCR pathogen detection is useful as an
adjunct to blood cultures to support early adjust-
ment of empiric antimicrobial therapy.
• The incremental cost is justified for patients with
over 25% inadequate initial treatment, especially in
the presence of high daily treatment cost and risk of
severe complications from inadequate treatment.
• The prediction model provides guidance when
designing and evaluating interventional trials that
incorporate PCR into managing antimicrobial treat-
ment in sepsis. It can also be used to explore relative
utility and price-worthiness of alternative molecular
assays, or of how to best implement them into
laboratory routines.
Additional material
Additional file 1: Cost per PCR test. This additional file explains the
cost components for one PCR test. Furthermore, two graphs represent
how the key results would change with different PCR costs.
Additional file 2: Substitution factors. Description: For institutions that
presently have only culture based data available, the substitutions in this
additional data file allow utilization of the model to estimate potential
gains from PCR.
Abbreviations
€: Euro (European currency unit); BC: blood culture (BC+: blood culture with
clinically relevant microorganism identified, not counting contaminations
that are immediately at reporting evident to the treating clinician); CI:
confidence interval; CoNS: coagulase-negative Staphylococcus; Costsurv: total
(PCR related, incremental) costs that are incurred per incremental survivor;
ICER: incremental cost-effectiveness ratio; ICU: intensive care unit; LOS:
length of stay (of a patient in a department, or in the hospital); MRSA:
methicillin-resistant Staphylococcus aureus; Nepis: total number of episodes
(and tests) in which blood cultures are complemented by PCR testing for
managing early antimicrobial treatment in sepsis; PCR: polymerase chain
reaction (PCR+: PCR with clinically relevant microorganism identified. Note
that in our study, all PCR+ reported microorganisms are considered clinically
relevant); QALY: quality-adjusted life year.
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